Correlation Between Apellis Pharmaceuticals and CRISPR Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Apellis Pharmaceuticals and CRISPR Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Apellis Pharmaceuticals and CRISPR Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Apellis Pharmaceuticals and CRISPR Therapeutics AG, you can compare the effects of market volatilities on Apellis Pharmaceuticals and CRISPR Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Apellis Pharmaceuticals with a short position of CRISPR Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Apellis Pharmaceuticals and CRISPR Therapeutics.

Diversification Opportunities for Apellis Pharmaceuticals and CRISPR Therapeutics

  Correlation Coefficient

Very good diversification

The 3 months correlation between Apellis and CRISPR is -0.24. Overlapping area represents the amount of risk that can be diversified away by holding Apellis Pharmaceuticals and CRISPR Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CRISPR Therapeutics and Apellis Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Apellis Pharmaceuticals are associated (or correlated) with CRISPR Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CRISPR Therapeutics has no effect on the direction of Apellis Pharmaceuticals i.e., Apellis Pharmaceuticals and CRISPR Therapeutics go up and down completely randomly.

Pair Corralation between Apellis Pharmaceuticals and CRISPR Therapeutics

Given the investment horizon of 90 days Apellis Pharmaceuticals is expected to generate 1.04 times more return on investment than CRISPR Therapeutics. However, Apellis Pharmaceuticals is 1.04 times more volatile than CRISPR Therapeutics AG. It trades about 0.05 of its potential returns per unit of risk. CRISPR Therapeutics AG is currently generating about 0.0 per unit of risk. If you would invest  3,840  in Apellis Pharmaceuticals on July 4, 2022 and sell it today you would earn a total of  2,990  from holding Apellis Pharmaceuticals or generate 77.86% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
ValuesDaily Returns

Apellis Pharmaceuticals  vs.  CRISPR Therapeutics AG

 Performance (%) 
Apellis Pharmaceuticals 
Apellis Performance
12 of 100
Compared to the overall equity markets, risk-adjusted returns on investments in Apellis Pharmaceuticals are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak essential indicators, Apellis Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point.

Apellis Price Channel

CRISPR Therapeutics 
CRISPR Performance
0 of 100
Over the last 90 days CRISPR Therapeutics AG has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, CRISPR Therapeutics is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the insiders.

CRISPR Price Channel

Apellis Pharmaceuticals and CRISPR Therapeutics Volatility Contrast

   Predicted Return Density   

Pair Trading with Apellis Pharmaceuticals and CRISPR Therapeutics

The main advantage of trading using opposite Apellis Pharmaceuticals and CRISPR Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Apellis Pharmaceuticals position performs unexpectedly, CRISPR Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will offset losses from the drop in CRISPR Therapeutics' long position.
Apellis Pharmaceuticals vs. Anglo American Plc
Apellis Pharmaceuticals vs. Vale SA ADR
Apellis Pharmaceuticals vs. Pt United Trac
Apellis Pharmaceuticals vs. Teck Resources
The idea behind Apellis Pharmaceuticals and CRISPR Therapeutics AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
CRISPR Therapeutics vs. Randstad NV
CRISPR Therapeutics vs. General Employment Enterprises
CRISPR Therapeutics vs. Hays Plc
CRISPR Therapeutics vs. Paychex
Check out your portfolio center. Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Other Complementary Tools

Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities